Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
3 Growth Stocks Set to Flourish
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced...
Halozyme Therapeutics: Q1 Earnings Snapshot
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026